TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Serum testosterone levels (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Nestorone levels (Cavg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Nestorone levels (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Nestorone levels (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sickness leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Androgen secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Protein secretion from liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of altered perception of orgasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of orgasm related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of impairing deviations or loss of length of the penis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of Nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with positive SARS-CoV-2 serodiagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete Pathological Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with mean bio-intact parathyroid hormone (biPTH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: reductive rate of Hamilton Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurance of second primary malignancy
Endpoint domain: Adverse events/effects
Primary endpoint: Participant disease response assessment results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of rumination events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: TDI E' ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Facility-level inappropriate prostate cancer imaging rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Facility-level appropriate prostate cancer imaging rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum measurable plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Final Value of Serum Apolipoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Reduction in PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in mixed-obstructive apnea index (MOAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative Treatment Failure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: colonic geometric center (GC) at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ascending colon t1/2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With Clinical Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall subject's assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with regular follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in ADAS-Cog14 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glycemic control measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Concern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinical Chemistry and Hematology Parameter Values of Potential Clinical Concern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Amniotic Fluid Index (AFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of the breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GDF-15 concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Oswestry Low Back Pain Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Achieve Independent Sitting for at Least 10 Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight from baseline at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in length of anthropometrics from baseline at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change head circumference of anthropometrics from baseline at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Violence From School Staff
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Abnormal Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Successful Study Device Access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful Study Device Deployment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary Procedural Side Branch Patency as Assessed by Angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: changes in 6-minute walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days Until 50% Healing of Leg Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of low back and pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shear index between SSCT and FDS3 tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of infants with treatment-limiting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of infants with at least a 1.5 log10 copies/mL reduction in HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of infants with trough drug concentrations below therapeutic ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of middle meatal synechiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in the Number of Actinic Keratosis at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in the Number of Actinic Keratosis at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety and tolerability of ASN008 topical gel
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of end stage renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Subjects With Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Fatal SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose concentrations during oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With a Response (CR and CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hepatic Adverse Event-free Survival at Day 42
Endpoint domain: Mortality/survival
Primary endpoint: Test for Infant Motor Performance Screening Items (TIMPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chlamydia or gonorrhea infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the maximal rate of myocardial oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MRI changes of left and right ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CMR parameters changes of the right and left ventricle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrical substrate changes of the right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predicted Cardiovascular Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Sensitivity and Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of phantom limb pain (PLP) and/or residual limb pain (RLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level (Visual Analogue Scale [VAS]) of PLP and/or RLP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of presence and control status for known risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Polyphenol Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Excretion of Total Polyphenols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Total Fecal Polyphenols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization days per year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Tolerability- The rate of discontinuation of patients' participation in the study due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Right ventricle assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shear modulus measurement in multifidus and erector spinae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Genetic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak drug concentration (Cmax) of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the drug plasma concentration-time curve (AUC) of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of pesticides in mother's milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary Patency of InnAVasc AVG at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events of Special Interest (AESIs) Through 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Reproducibility of brain functional connectivity measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change of range of motion from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of rhythm recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' knowledge on life-threatening rhythms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postoperative SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in PDUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in DAS28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in erythropoietin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Drop of white blood cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acceptability of the Zinc Dispersible Tablet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decisional Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with Preparation for Decision Making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Development of PDAC
Endpoint domain: Mortality/survival
Primary endpoint: Implants survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Change in Score on the 17-item Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants with Actionable Eye Disease (AED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Fecal Incontinence Severity Index (FISI) at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Incontinence Severity Index (FISI) at Follow-Up (FU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Maximum Concentration (Cmax) of Ertapenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Minimum Concentration (Cmin) of Ertapenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Curve (AUC) of Ertapenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity as assessed by the Dyspnea Modified Borg Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity as assessed by the Overall Fatigue Modified Borg Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current self-reported health status as measured by the Fagerström Test for Nicotine Dependence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subject retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MOD Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T cell profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Contrastation analysis of the arterial lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infectious incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical respiratory depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SEP amplitude in burst-suppression-EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caloric intake for Lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in expression of proteins associated with inflammation, proliferation and cancer development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression and activity of TF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant Knowledge about Tubal Sterilization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Decisional Conflict in Postpartum Contraceptive Choice
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective tumour response (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Experienced Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved a Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Involvement in screening decision
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Amount of vaccine virus shed by each participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bacterial viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of new self-sustaining wellness and exercise programs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall survival at 42 days
Endpoint domain: Mortality/survival
Primary endpoint: Area Under Plasma Concentration-time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma (Peak) Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change of Hemoglobin A1C (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: the Occurrence of Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Children's sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction of other symptoms of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive Predictive Value of the hypo-Sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1 relaxometry value of Region of Interest (ROI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2 relaxometry value of Region of Interest (ROI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean absolute change in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new hemorrhagic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPD Exacerbation Rate (Moderate or Severe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal movement of implanted endograft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of used anesthetic gas (desflurane)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pediatric Early Warning Scores (PEWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at 1 Year Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with periinterventional serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with freedom from recurrence from type I atrial flutter 3 months after ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in body strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes